Trent Reutiman appointed as new CEO

Anaconda Biomed is honored to announce the appointment of  Trent Reutiman, a veteran medical technology industry executive, as its new CEO. Based in California’s San Francisco Bay Area, Reutiman will establish a new footprint for the company in the U.S. as it works towards regulatory approval of its ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter Technology), a catheter-based technology designed to improve neurovascular interventions by enhancing the capabilities of existing and forthcoming intravascular neuro devices.

Reutiman brings more than twenty-five years of executive, financial, market development, and sales operation leadership experience to Anaconda, with an extensive focus in vascular technologies. Prior to his new position, he was the CEO of Mercator MedSystems Inc., where he oversaw the development of the company’s catheter-based drug delivery system for treating peripheral artery disease (PAD) and other venous vascular conditions, raised consecutive rounds of capital, and negotiated a financing and strategic partnership with China-based Shenzhen Salubris Pharmaceuticals Co. (Salubris). Previously, he was VP of global commercial operations for IDEV, a company solving unmet revascularization needs in PAD, which was acquired by Abbott in 2013. Reutiman has also served in leadership roles at ROX Medical, OmniSonics Medical Technologies, and RITA Medical Systems. He holds a bachelor’s degree in business and economics from Colorado State University and a Master of Business Administration degree from the University of California, Irvine.

Reutiman replaces Anaconda’s previous CEO Francois Salmon, who will now serve as the company’s Board Chairman.

Salmon added, “Trent is joining Anaconda at a pivotal time as we advance our clinical program and build evidence supporting FDA approval of the ANA Funnel Catheter in the U.S. On behalf of myself and the rest of the board, we welcome his leadership and contributions moving forward.”

Press Release